Table 1.
Correlation of Patient- and Treatment-Related Factors and SNHL (102 Ears)
| Variables | SNHL in Ears |
SNHL in Patients |
||||||
|---|---|---|---|---|---|---|---|---|
| SNHL/No | OR | 95% CI | P | SNHL/No | OR | 95% CI | P | |
| Age (years) | ||||||||
| > 40 | 11/45 | 5.38 | 1.28-25.67 | .034 | 7/21 | 7.33 | 0.83-64.80 | .059⁎ |
| ≤ 40 | 2/44 | 1 | 1/22 | 1 | ||||
| Gender | ||||||||
| Male | 9/67 | 0.74 | 0.21-2.64 | .735⁎ | 5/33 | 0.51 | 0.10-2.49 | .327⁎ |
| Female | 4/22 | 1 | 3/10 | 1 | ||||
| T stage (UICC 2002) | ||||||||
| 1-3 | 6/72 | 0.20 | 0.06-0.68 | .011⁎ | 4/35 | 0.23 | 0.05-1.12 | .076⁎ |
| 4 | 7/17 | 1 | 4/8 | 1 | ||||
| Stage (UICC 2002) | ||||||||
| IIa-III | 8/68 | 0.31 | 0.15-1.67 | .308⁎ | 5/33 | 0.51 | 0.10-2.49 | .404⁎ |
| IVa-IVb | 5/21 | 1 | 3/10 | 1 | ||||
| Treatment | ||||||||
| CCRT | 2/42 | .015 | 1/21 | .095 | ||||
| IC → CCRT | 9/45 | 6/21 | ||||||
| IC → CCRT → AC | 2/2 | 1/1 | ||||||
| Cumulative cisplatin dose (mg/m2) | ||||||||
| More than 200 | 11/35 | 8.49 | 1.77-40.61 | .003 | 7/16 | 5.67 | 1.05-30.84 | .061⁎ |
| Less than 200 | 2/54 | 1 | 2/26 | 1 | ||||
| Cisplatin prescribed regimen in CCRT | ||||||||
| Weekly cisplatin | 0/16 | .213⁎ | 1/6 | 0.88 | 0.09-8.49 | 1.000⁎ | ||
| Every 3 wk | 13/73 | 7/37 | 1 | |||||
| Carboplatin | ||||||||
| With carboplatin | 3/19 | 1.11 | 0.28-4.42 | 1.000⁎ | 2/9 | 1.26 | 0.22 -7.33 | .557⁎ |
| Without carboplatin | 10/70 | 1 | 6/34 | 1 | ||||
| Treatment time | ||||||||
| Within 6 wk | 7/27 | 2.68 | 0.82-8.72 | .118 | 4/13 | 2.31 | 0.50-10.67 | .416⁎ |
| More than 6 wk | 6/62 | 1 | 4/30 | 1 | ||||
Abbreviations: CT, chemotherapy; CCRT, concurrent chemoradiotherapy; IC → CCRT, induction chemotherapy followed by chemoradiotherapy; IC → CCRT → AC, induction chemotherapy followed by chemoradiotherapy plus adjuvant chemotherapy; UICC, Union for International Cancer Control.
⁎
Fisher’s exact test was used for comparison.